To observe whether PCSK9 inhibitor combined with statin therapy can bring additional benefits on near-term clinical prognosis in patients with acute cerebral infarction，in order to provide clinical data on the effects of PCSK9 inhibitors in the early treatment of patients with cerebral infarction. Methods124 patients with acute cerebral infarction admitted to the neurology ward of our hospital from December 2020 to July 2021 were included as study subjects. A 90-day clinical follow-up was used to compare the differences in hematological indices，clinical neurological function scores，documentation of recurrent cerebral infarction and other thrombotic events during the follow-up period and differenses in the time to recurrence between the PCSK9 inhibitor combined with statin treatment and standard statin treatment groups. ResultsThe levels of hs-CRP，IL-6，Lp-PLA2，HCY，TC and LDL-C，NIHSS score and mRS score in the PCSK9 inhibitor combined with statin treatment group and the standard statin treatment group were all decreased before and after treatment（P<0.05），and there was a statistically significant difference in the combined treatment group（P<0.05），and lowered TG（P<0.05），while the level of HDL-C was improved（P<0.05）. There was no statistical significance in fasting plasma glucose of both groups before and after treatment（P>0.05）. Compared with the combined treatment group，the recurrence rate of cerebral infarction in the standard treatment group was obviously high（χ2=7.694，P=0.006），while the time to cerebral infarction recurrence was significantly longer in the combined treatment group（P<0.05）. ConclusionPCSK9 inhibitors can effectively reduce peripheral inflammatory response，promote neurological function recovery，significantly reduce stroke recurrence rate，and significantly prolong the recurrence time.